Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

0.3562 -0.0339 (-8.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,519,948
Open 0.3901
Bid (Size) 0.3700 (10)
Ask (Size) 0.3730 (1)
Prev. Close 0.3901
Today's Range 0.3500 - 0.4035
52wk Range 0.3500 - 2.210
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
From 23andMe, Inc.
Via GlobeNewswire
Looking Into 23andMe Holding's Recent Short Interest
Via Benzinga

Performance

YTD
-60.79%
-60.79%
1 Month
-24.36%
-24.36%
3 Month
-44.11%
-44.11%
6 Month
-55.39%
-55.39%
1 Year
-82.71%
-82.71%

More News

Read More
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
Via The Motley Fool
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
From 23andMe, Inc.
Via GlobeNewswire
Looking Into 23andMe Holding's Recent Short Interest
Via Benzinga
Is 23andMe Stock a Smart Buy Right Now?
Via The Motley Fool
Recap: 23andMe Holding Q3 Earnings
Via Benzinga
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
From 23andMe, Inc.
Via GlobeNewswire
A Few Years From Now, You'll Probably Wish You'd Followed Billionaire Investors Into This Stock
Via The Motley Fool
23andMe Launches New Genetic Reports on Common Forms of Cancer
From 23andMe, Inc.
Via GlobeNewswire
Earnings Scheduled For February 7, 2024
Via Benzinga
A Preview Of 23andMe Holding's Earnings
Via Benzinga
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
From 23andMe, Inc.
Via GlobeNewswire
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Former YouTube CEO's Teenaged Son Found Dead At UC Berkeley
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Crude Oil Gains 3%; Kellanova Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Dow Tumbles Over 100 Points; US Initial Jobless Claims Fall Last Week
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
23andMe Reports Third Quarter Fiscal 2024 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Why Is Invitae (NVTA) Stock Down 75% Today?
Via InvestorPlace
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Troubled Biotech Company's Investigational Cancer Drug Gets Greenlighted By FDA
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.